Lenvatinib mesylate is used to treat hepatocellular carcinoma, non-small cell lung cancer, melanoma, breast cancer, lymphoma, ovarian cancer, etc.
Lenvatinib mesylate is a multi-target tyrosine kinase inhibitor with a novel binding mode that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2 and VEGF-3, in addition to inhibiting other proangiogenic and oncogenic signaling pathway-related tyrosine kinases involved in tumor proliferation.
|Package details:||1g/vial; 10g/PE bottle|
Used as antineoplastic agents.
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!